On Tuesday, Shares of Illinois Tool Works Inc. (NYSE:ITW), gained 0.16% to $94.16.
Miller has added another reason to celebrate the holidays: free gifts with qualifying purchases at MillerWelds.com. Customer orders of $50 or more mean a gift of Blue for someone. The bigger the purchase, the more gifts a customer will receive. Every standard ground-shippable order still costs just $4.99 to send.
Recently through Dec. 31, 2015, customers will receive the following gifts with qualifying purchase:
- Spend $50-$250 – Free hat
- Spend $250-$500 – Free hat and $25 gift card
- Spend $500 or more – Free hat, tumbler and $50 gift card
Last-minute shoppers can breathe easy. For orders placed between Dec. 14 and 18, Miller will offer guaranteed delivery by Dec. 24 using the flat rate shipping. Learn more recently at MillerWelds.com/holiday.
Illinois Tool Works Inc. manufactures and sells industrial products and equipment worldwide. It operates through seven segments: Automotive OEM; Test & Measurement and Electronics; Food Equipment; Polymers & Fluids; Welding; Construction Products; and Specialty Products.
Shares of Sangamo Biosciences, Inc. (NASDAQ:SGMO), inclined 11.35% to $9.22, during its last trading session.
Sangamo Bio Sciences, declared that the U.S. Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug (IND) application for SB-FIX, a potentially curative, single treatment therapy for hemophilia B. SB-FIX is the first in vivo genome editing application to enter the clinic and is based on Sangamo’s proprietary In Vivo Protein Replacement Platform™ (IVPRP™). The IND is now active and enables Sangamo to initiate a Phase 1/2 clinical study (SB-FIX-1501) designed to assess safety, tolerability and potential efficacy of SB-FIX in adults with hemophilia B.
“We are very happy to be in a position to initiate a clinical trial of our hemophilia B program which will not only be the first clinical application of our IVPRP but the first human study of any in vivo genome editing application,” said Edward Lanphier, Sangamo’s president and chief executive officer. “The FDA’s determination that our planned clinical trial may proceed is not only an important milestone for Sangamo’s hemophilia program, but is a major de-risking event for our entire IVPRP as we are able to leverage this same approach to develop ZFP Therapeutics® for hemophilia A and numerous lysosomal storage disorders (LSDs). This is a noteworthyachievement for the fields of genome editing and gene therapy, and marks a new era in genetic medicine.”
SB-FIX-1501 is a Phase 1/2 open-label, dose-escalation study in male subjects over eighteen years of age, with severe hemophilia B, who do not have inhibitors to FIX and have no hypersensitivity to recombinant Factor IX (rFIX) protein. The study, which will start enrolling up to nine subjects in 2016, will evaluate the safety and efficacy of a single administration of SB-FIX. The principal investigators are Nadia Ewing, M.D., Director, Comprehensive Hemophilia Treatment Center and Sickle Cell Program, and John Zaia, M.D., Director, Center for Gene Therapy at City of Hope in Duarte, California. The ZFP Therapeutic comprises the therapeutic FIX replacement gene and zinc finger nucleases (ZFNs) formulated as adeno-associated virus (AAV) vector preparations and will be administered as a single intravenous dose.
Sangamo Bio Sciences, Inc., a clinical stage biopharmaceutical company, focused on the research, development, and commercialization of engineered DNA-binding proteins as novel therapeutic products for various monogenic and infectious diseases with unmet medical needs. Its proprietary zinc finger DNA-binding protein (ZFP) technology enables precise and highly specific genome modification and gene regulation.
Finally, Shares of Deere & Company (NYSE:DE), ended its last trade with -0.09% loss, and closed at $79.50.
Deere & Company, said it has informed about 220 employees at John Deere Seeding and Cylinder in Moline that they will be placed on indefinite layoff, effective February 15, 2016. Employees were informed of the layoff recently in meetings at the Moline facility.
The layoffs reflect last week’s forecast by Deere that agricultural machinery sales will decrease in fiscal year 2016. Deere said the actions are taken to align the size of the manufacturing workforce at individual factories with market demand for products made at each specific location.
In the past, manufacturing employees at John Deere Seeding and Cylinder have practiced seasonal layoffs in the spring and returned to work in the fall. Recently’s declaration is an indefinite layoff with no specific call-back date.
Deere & Company, together with its auxiliaries, manufactures and distributes agriculture and turf, and construction and forestry equipment worldwide. The company’s Agriculture and Turf segment provides agriculture and turf equipment, and related service parts, counting large, medium, and utility tractors; loaders; combines, corn pickers, cotton and sugarcane harvesters, and related front-end equipment and sugarcane loaders; and tillage, seeding, and application equipment, counting sprayers, nutrient administration, and soil preparation machinery.